Form D · Biotechnology

Aegle Therapeutics Corp

Woburn, MA · CIK 0001797825

Offering snapshot reported Aug 28, 2026 · SEC filing

Reported sold
$2.28M
Offering amount: $2.28M
Investors reported
17
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 4, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 28, 2026Initial$2,277,698No comparison17SEC filing
Mar 3, 2026Initial$455,695No comparison10SEC filing
Jul 28, 2020Amendment$6,500,000$1,500,000vs May 14, 20208SEC filing
May 14, 2020Amendment$5,000,000$990,000vs Jan 7, 20208SEC filing
Jan 7, 2020Initial$4,010,000No comparison7SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595786

Source: Form D, filed Aug 28, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Evangelos Badiavas Director
Elona Baum Director
Scott Braunstein Director
Shelley Hartman Director, Executive
Leon Moulder Director
Leon Moulder, Jr. Director
Steve O'hara Director
Robert Ryan Director
David Schimel Director
Mikio Tanji Director
Robert Williamson, Jr. Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
400 Tradecenter Suite 5900
Woburn, MA, 01801
Phone: 781-918-8449